Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients
- PMID: 34864924
- PMCID: PMC9402662
- DOI: 10.1093/cid/ciab1000
Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients
Comment in
-
Reply to Caldwell et al.Clin Infect Dis. 2022 Aug 24;75(1):180-181. doi: 10.1093/cid/ciab1001. Clin Infect Dis. 2022. PMID: 34864913 Free PMC article. No abstract available.
Comment on
-
Colonization With Fluoroquinolone-Resistant Enterobacterales Decreases the Effectiveness of Fluoroquinolone Prophylaxis in Hematopoietic Cell Transplant Recipients.Clin Infect Dis. 2021 Oct 5;73(7):1257-1265. doi: 10.1093/cid/ciab404. Clin Infect Dis. 2021. PMID: 33956965 Free PMC article.
References
-
- Schelenz S, Nwaka D, Hunter PR.. Longitudinal surveillance of bacteraemia in haematology and oncology patients at a UK cancer centre and the impact of ciprofloxacin use on antimicrobial resistance. J Antimicrob Chemother 2013; 68:1431–8. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical